1
|
Catella J, Guillot N, Nader E, Skinner S, Poutrel S, Hot A, Connes P, Fromy B. Controversies in the pathophysiology of leg ulcers in sickle cell disease. Br J Haematol 2024; 205:61-70. [PMID: 38867511 DOI: 10.1111/bjh.19584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 05/27/2024] [Indexed: 06/14/2024]
Abstract
Patients with sickle cell disease (SCD) often experience painful vaso-occlusive crises and chronic haemolytic anaemia, as well as various acute and chronic complications, such as leg ulcers. Leg ulcers are characterized by their unpredictability, debilitating pain and prolonged healing process. The pathophysiology of SCD leg ulcers is not well defined. Known risk factors include male gender, poor social conditions, malnutrition and a lack of compression therapy when oedema occurs. Leg ulcers typically start with spontaneous pain, followed by induration, hyperpigmentation, blister formation and destruction of the epidermis. SCD is characterized by chronic haemolysis, increased oxidative stress and decreased nitric oxide bioavailability, which promote ischaemia and inflammation and consequently impair vascular function in the skin. This cutaneous vasculopathy, coupled with venostasis around the ankle, creates an ideal environment for local vaso-occlusive crises, which can result in the development of leg ulcers that resemble arterial ulcers. Following the development of the ulcer, healing is hindered as a result of factors commonly observed in venous ulceration, including venous insufficiency, oedema and impaired angiogenesis. All of these factors are modulated by genetic factors. However, our current understanding of these genetic factors remains limited and does not yet enable us to accurately predict ulceration susceptibility.
Collapse
Affiliation(s)
- Judith Catella
- Service de Médecine Interne et Vasculaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
- Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI UMR 5305), CNRS/Université Claude Bernard Lyon 1, Lyon, France
| | - Nicolas Guillot
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Elie Nader
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Sarah Skinner
- Clinical Research and Epidemiology Unit, Montpellier University, Montpellier, France
| | - Solène Poutrel
- Service de Médecine Interne et Vasculaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Arnaud Hot
- Service de Médecine Interne et Vasculaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Philippe Connes
- Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), Sorbonne, Paris, France
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Berengère Fromy
- Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI UMR 5305), CNRS/Université Claude Bernard Lyon 1, Lyon, France
| |
Collapse
|
2
|
Reis de Souza V, Kelly S, Cerdeira Sabino E, Mendes de Oliveira F, Silva T, Miranda Teixeira C, Máximo C, Loureiro P, Barbara de Freitas Carneiro-Proietti A, Gomes I, Custer B, de Almeida-Neto C. Factors Associated with Leg Ulcers in Adults with Sickle Cell Disease in Brazil. Adv Skin Wound Care 2023; 36:98-105. [PMID: 36662043 DOI: 10.1097/01.asw.0000911152.41719.e5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVE To define the prevalence of leg ulcers and identify the clinical and laboratory factors associated with leg ulcers in adult participants. METHODS The authors conducted a cross-sectional study of 1,109 patients who were 18 years or older with SS or Sβ0-thalassemia genotypes from a Brazilian cohort. Investigators assessed the prevalence of factors associated with leg ulcers from 2013 to 2017. RESULTS The prevalence of leg ulcers was 21%. Increasing age (odds ratio [OR], 1.07; range, 1.06-1.09), male sex (OR, 2.03; range, 1.44-2.87), treatment with chronic transfusion therapy (OR, 1.88; range, 1.15-3.03), higher indirect bilirubin levels (OR, 1.48; range, 1.02-2.16), and low hemoglobin levels (OR, 2.17; range, 1.52-3.11) were associated with leg ulcers. Participants who self-reported as Black (OR, 6.75; range, 2.63-21.32), mixed (OR, 3.91; range, 1.55-12.20), and other/unknown (OR, 3.84; range, 1.04-15.24) were more likely to have leg ulcers compared with those who self-reported as White. CONCLUSIONS The prevalence of leg ulcers in this Brazilian cohort was higher than the prevalence reported in developed countries. Known factors such as age and male sex were corroborated. The increased bilirubin level and decreased hemoglobin levels among participants with leg ulcers support the hypothesis that hemolysis is correlated with leg ulcer pathogenesis. Self-reported black skin color was an independent predictor of leg ulcers and warrants further study to understand the etiology and implications of this finding.
Collapse
Affiliation(s)
- Valquíria Reis de Souza
- Valquíria Reis de Souza, MSc, is Biologist, Instituto de Medicina Tropical, University of São Paulo, Brazil. Shannon Kelly, MD, is Associate Professor, Pediatrics, Vitalant Research Institute, San Francisco, California. Also at Instituto de Medicina Tropical, University of São Paulo, Ester Cerdeira Sabino, MD, PhD, is Associate Professor and Franciane Mendes de Oliveira, BSc, is Master's Degree Student. Tassila Silva, PhD, is Assistant Professor, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte. Carolina Miranda Teixeira, MSc, is Biologist and Master, Faculdade de Medicina, Universidade Federal de Minas Gerais. Claudia Máximo, MD, is Hematologist at Hemorio, Hemocentro do Rio de Janeiro. Paula Loureiro, MD, PhD, is Adjunct Professor and Researcher at Hemope and Universidade de Pernambuco, Recife. Also at Fundação Hemominas, Hemocentro de Minas Gerais, Anna Barbara de Freitas Carneiro-Proietti, MD, PhD, is Senior Researcher. Isabel Gomes, PhD, is Researcher at Universidade Federal de Minas Gerais. Brian Custer, PhD, MPH, is Director, Vitalant Research Institute, San Francisco, California and Professor of Laboratory Medicine, University of California, San Francisco. Cesar de Almeida-Neto, MD, PhD, is Associate Professor at Faculdade de Medicina da Universidade de São Paulo and Chief of Apheresis Department at Fundação Pró-Sangue Hemocentro de São Paulo. Acknowledgment: This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute by grant HHSN268201100007I. Recipient Epidemiology and Donor Evaluation Study-III: International Component (Brazil), with the participation of the following centers and investigators. Brazilian participants: Instituto de Medicina Tropical de São Paulo (USP): Ester C. Sabino, Cecilia Alencar; Fundação Pró-Sangue (São Paulo): Alfredo Mendrone, Jr, Cesar de Almeida Neto, Ligia Capuani; Instituto de Tratamento do Câncer Infantil (São Paulo): Miriam Park; Faculdade de Medicina da Universidade de São Paulo (São Paulo): Paula Blatyta; Hemominas-Belo Horizonte (Minas Gerais): Anna Bárbara de Freitas Carneiro-Proietti, Andre Belisario, Carolina Miranda Teixeira, Tassila Salomon, Franciane Mendes de Oliveira, Valquíria Reis. Hemominas; Montes Claros (Minas Gerais): Rosemere Afonso Mota, José Wilson Sales; Hemominas-Juiz de Fora (Minas Gerais): Daniela de Oliveira Werneck; Fundação Hemope-Recife (Pernambuco): Paula Loureiro, Aderson Araújo, Dahra Teles Hemorio (Rio de Janeiro): Clarisse Lobo, Claudia Máximo, Luiz Amorin; Instituto de Matemática e Estatística da Universidade de São Paulo-USP (São Paulo): João Eduardo Ferreira, Márcio Katsumi Oikawa, Pedro Losco Takecian, Mina Cintho Ozahata, Rodrigo Muller de Carvalho. US Investigators: Vitalant Research Institute and University of California San Francisco: Brian Scott Custer, Michael P. Busch, and Thelma Therezinha Gonçalez; Research Triangle Institute: Donald Brambilla, Liliana R. Preiss, Christopher McClure; UCSF Benioff Children's Hospital Oakland: Shannon Kelly; National Heart, Lung, and Blood Institute-Simone A. Glynn. The authors have disclosed no other financial relationships related to this article. Submitted February 16, 2022; accepted in revised form August 12, 2022
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Cutaneous manifestations of sickle cell disease: an updated review. Arch Dermatol Res 2022; 315:729-734. [PMID: 36416981 DOI: 10.1007/s00403-022-02466-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 10/26/2022] [Accepted: 11/07/2022] [Indexed: 11/24/2022]
Abstract
Sickle cell disease is a common and highly morbid genetic condition that is characterized by multi-system involvement, including numerous cutaneous manifestations. Persistent and recurrent leg ulceration has long been considered the dermatological hallmark of those with sickle cell disease, but there have been recent descriptions of associated infection with rare pathogens and episodes of liverdoid vasculopathy. Growing considerations for this population in the literature include cutaneous reactions to common treatments such as hydroxyurea and clinical management of the intersection between sickle cell disease and conditions like plaque psoriasis. Recent studies have also demonstrated an increased resistance to skin carcinogenesis for those with sickle cell disease through unclear mechanisms. However, though the body of knowledge regarding cutaneous manifestations and considerations of sickle cell disease is slowly expanding, it does not match the considerable disease and symptom burden faced by these patients. More research is needed to better delineate our understanding of these cutaneous manifestations of sickle cell disease to improve outcomes and further management.
Collapse
|
4
|
Ongarora BG. Recent technological advances in the management of chronic wounds: A literature review. Health Sci Rep 2022; 5:e641. [PMID: 35601031 PMCID: PMC9117969 DOI: 10.1002/hsr2.641] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 04/13/2022] [Accepted: 04/18/2022] [Indexed: 11/10/2022] Open
Abstract
Background Wound treatment comprises a substantial portion of the healthcare budgets in developed countries. Studies suggest that about 50% of patients admitted to hospitals have wounds, while 1%−2% of the general population in the developed world suffers from chronic wounds. Chronic wounds fail to repair themselves within the expected period of 30 days. Technologies have been developed to address challenges encountered during wound care with the aim of alleviating pain, promoting healing, or controlling wound infections. Objective The objective of this study was to explore the technological improvements that have been made in this field over time. Methods To gain insight into the future of wound management, a systematic review of literature on the subject was conducted in scientific databases (PubMed, Scopus, Web of Science, Medline, and Clinical Trials). Results and Discussion Results indicate that wound dressings have evolved from the traditional cotton gauze to composite materials embedded with appropriate ingredients such as metal‐based nanoparticles. Studies on biodegradable dressing materials are also underway to explore their applicability in dressing large and irregular wounds. On the other hand, conventional drugs and traditional formulations for the management of pain, inflammation, infections, and accelerating healing have been developed. However, more research needs to be carried out to address the issue of microbial resistance to drugs. Drugs for managing other ailments also need to be designed in such a way that they can augment wound healing. In addition, it has been demonstrated that a coordinated integration of conventional and traditional medicine can produce laudable results in chronic wound management. Conclusion Accordingly, collaborative efforts and ingenuity of all players in the field can accelerate technological advances in the wound care market to the benefit of the patients. Wounds affect about 50% of patients admitted to hospitals.
Technologies have been developed including biodegradable dressing materials to address underlying challenges.
Technological advancement, rising incidences of chronic wounds, growing government support, and a rising elderly population will drive wound market growth.
A careful combination of recent research outputs can greatly change wound care technologies.
This review highlights the recent research advances and opportunities in the wound care field.
The future lies in biodegradable dressing materials, probably embedded with selected nanoparticles and which shall be combined in predetermined ratios.
Collapse
Affiliation(s)
- Benson G. Ongarora
- Department of Chemistry Dedan Kimathi University of Technology Nyeri Kenya
| |
Collapse
|
5
|
Tolu SS, Crouch A, Choi J, Gao Q, Reyes-Gil M, Ogu UO, Vinces G, Minniti CP. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease. Ann Hematol 2022; 101:541-548. [PMID: 35039901 DOI: 10.1007/s00277-021-04635-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Accepted: 08/14/2021] [Indexed: 11/01/2022]
Abstract
The presence of leg ulcers in individuals with sickle cell disease often represents an early sign of vasculopathy and future end organ damage. Pathophysiological mechanisms of formation and evolution of leg ulcers are poorly understood; nevertheless, HbF has been associated with lower incidence of leg ulcers, while hydroxyurea has been correlated with high risk of leg ulcers. As a result, there is hesitation regarding hydroxyurea use in patients with SCD and leg ulcers. In this study, we aim to define (1) a target of HbF that offers protection against leg ulcer development and (2) the impact of hydroxyurea therapy on leg ulcer prevalence. Our study demonstrated that in order to reduce leg ulcer incidence by one-third, a HbF > 25% is needed, a threshold not commonly reached and maintained in the adult SCD population. Importantly, leg ulcer incidence appears to be independent of HU use (p = 0.50). Our interpretation of this data is that the use of HU in a patient with SCD and leg ulcers should be guided by a careful assessment of risks and benefits of this therapeutic modality.
Collapse
Affiliation(s)
- Seda S Tolu
- Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, 111 East 210th street, Bronx, NY, 10467, USA.
| | - Andrew Crouch
- Department of Medicine, Division of Hematology, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Jaeun Choi
- Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Qi Gao
- Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Moramaya Reyes-Gil
- Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
| | - Ugochi Olivia Ogu
- Department of Medicine, Division of Hematology/Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Giacomo Vinces
- Department of Family and Social Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
| | - Caterina P Minniti
- Department of Medicine, Division of Hematology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
| |
Collapse
|
6
|
Mehta V, Kirubarajan A, Sabouhanian A, Jayawardena SM, Chandrakumaran P, Thangavelu N, Cader R, Mettananda S, Bandara D, Khan S, Weatherall DJ, Allen A, Premawardhena AP, Olivieri NF. Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia. Acta Haematol 2021; 145:334-343. [PMID: 34753145 DOI: 10.1159/000520731] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 10/05/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Leg ulcers are a frequent complication in patients with the inherited hemoglobin disorders. In thalassemia, the literature is limited, and factors associated with the development of leg ulcers in hemoglobin E (HbE) beta thalassemia, the most common form of severe beta-thalassemia worldwide, have not previously been reported. METHODS We reviewed all available medical records of patients with HbE beta thalassemia to document the onset of leg ulcers at the 2 largest treatment centers in Sri Lanka. We reviewed the literature to identify studies reporting outcomes of interventions for ulcers in severe thalassemia. RESULTS Of a total of 255 actively registered patients with HbE thalassemia in the 2 centers, 196 patient charts were evaluable. A leg ulcer with a documented date of onset was recorded in 45 (22%) of 196 evaluable patients, aged (mean ± SEM) 22.2 ± 1.4 years. Most had been irregularly transfused; steady-state hemoglobin was 6.4 ± 0.2 g/dL. Treatment achieving healing in 17 patients included transfusions, antibiotics, oral zinc, wound toileting, and skin grafting. CONCLUSION Leg ulcers may be more common in HbE beta thalassemia than in other forms of thalassemia. A systematic approach to treatment will be needed to document the prevalence and factors placing such patients at risk for leg ulcers. Controlled trials to evaluate the optimal treatment of this common complication are indicated.
Collapse
Affiliation(s)
- Vikita Mehta
- Arts and Science, McMaster University, Hamilton, Ontario, Canada
| | | | - Amir Sabouhanian
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | | | | | - Nila Thangavelu
- Health Sciences, McMaster University, Hamilton, Ontario, Canada
| | - Refai Cader
- Policy Analysis and Development, Ministry of Health, Colombo, Sri Lanka
| | - Sachith Mettananda
- Department of Paediatrics, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | - Dayananda Bandara
- National Thalassaemia Centre, Kurunegala, Sri Lanka
- Teaching Hospital Kurunegala, Kurunegala, Sri Lanka
| | - Shawn Khan
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - David J Weatherall
- MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
| | - Angela Allen
- MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
| | | | - Nancy F Olivieri
- Pediatrics, Medicine and Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
7
|
Sahu T, Verma HK, Ganguly S, Sinha M, Sinha R. Common, But Neglected: A Comprehensive Review of Leg Ulcers in Sickle Cell Disease. Adv Skin Wound Care 2021; 34:423-431. [PMID: 34260420 DOI: 10.1097/01.asw.0000755924.12513.40] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVE To compile available evidence to better understand the management of leg ulcers in sickle cell disease (SCD), as well as describe potential therapeutic steps that may be required to improve the quality of life of patients with SCD leg ulcers. DATA SOURCES MEDLINE, PubMed, EMBASE, and Web of Science databases. STUDY SELECTION A comprehensive search was conducted to retrieve relevant studies using the keywords "sickle cell disease and leg ulcer," "ulcer treatments, diagnosis and sickle cell," and "wound sickle cell." Studies published through July 2020 were included. DATA EXTRACTION Two independent authors selected all studies that assessed the relationship between leg ulcer and SCD identified from online databases. DATA SYNTHESIS The authors have summarized updated information on pathophysiology (vasculopathy linked to chronic hemolysis and endothelial dysfunction), diagnosis, and available treatment options to unravel the dermohematologic connection between leg ulcers and SCD. CONCLUSIONS It is the authors' hope that this detailed discussion of the information available on leg ulcers and SCD will lead to a better appreciation of this clinical problem by the clinicians and researchers and in turn have a long-term positive effect on the quality of life of patients with SCD. Researchers should design new trials considering these insights and potential therapeutic approaches based on current knowledge.
Collapse
Affiliation(s)
- Tarun Sahu
- Tarun Sahu, PhD, is Research Fellow, Department of Physiology, All India Institute of Medical Sciences, Raipur, India. Henu Kumar Verma, PhD, is Researcher, Stem Cell Laboratory, Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, Italy. At the All India Institute of Medical Sciences, Satyaki Ganguly, MD, DNB, is Associate Professor, Department of Dermatology; Meenakshi Sinha, PhD, is Associate Professor, Department of Physiology; and Ramanjan Sinha, PhD, is Professor and Head, Department of Physiology. The authors have disclosed no financial relationships related to this article. Submitted August 26, 2020; accepted in revised form October 22, 2020
| | | | | | | | | |
Collapse
|
8
|
Development of Cutaneous Wound in Diabetic Immunocompromised Mice and Use of Dental Pulp-Derived Stem Cell Product for Healing. Methods Mol Biol 2021. [PMID: 32808255 DOI: 10.1007/978-1-0716-0845-6_3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2023]
Abstract
Chronic nonhealing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) in the United States costing $28-$32 billion annually. Despite advancement in wound management, approximately 8% of diabetic Medicare beneficiaries have a foot ulcer and 1.8% will have an amputation. The development of a regenerative approach is warranted to save these before-mentioned amputations. To this extent, herein, we describe the detailed methods in generating a type 1 diabetes mellitus (T1DM) condition in immunocompromised mice, inducing cutaneous wound, and application of dental pulp stem cell-derived secretory products for therapeutic assessment. This model helps in evaluating the efficacy of stem cell-based therapy and helps with the investigation of involved mechanisms in impaired cutaneous wound healing caused by hyperglycemic stress due to type 1 diabetes.
Collapse
|
9
|
Ogu UO, Badamosi NU, Camacho PE, Freire AX, Adams-Graves P. Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome. J Blood Med 2021; 12:101-114. [PMID: 33658881 PMCID: PMC7920619 DOI: 10.2147/jbm.s291394] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/07/2021] [Indexed: 12/14/2022] Open
Abstract
Sickle cell disease results in numerous complications that can lead to significant morbidity and mortality. Amongst them, acute chest syndrome is the leading cause of mortality. As a result, most providers are in tune with this complication and well versed with management. As sickle cell patients now live longer, they face a multitude of other complications that if left unattended, can lead to significant morbidity and mortality as well. It is critical to look beyond acute chest syndrome and adopt a more comprehensive approach to the management of the sickle cell patient.
Collapse
Affiliation(s)
- Ugochi O Ogu
- Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Nnenna U Badamosi
- Division of Pediatric Hematology and Oncology, Medical College of Georgia, Augusta, GA, USA
| | - Pamela E Camacho
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Amado X Freire
- Division of Pulmonary, Critical Care, and Sleep Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Patricia Adams-Graves
- Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA
| |
Collapse
|
10
|
Martí-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database Syst Rev 2021; 1:CD008394. [PMID: 34559425 PMCID: PMC8407242 DOI: 10.1002/14651858.cd008394.pub4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND The frequency of skin ulceration makes an important contributor to the morbidity burden in people with sickle cell disease. Many treatment options are available to the healthcare professional, although it is uncertain which treatments have been assessed for effectiveness in people with sickle cell disease. This is an update of a previously published Cochrane Review. OBJECTIVES To assess the clinical effectiveness and harms of interventions for treating leg ulcers in people with sickle cell disease. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. We searched LILACS (1982 to January 2020), ISI Web of Knowledge (1985 to January 2020), and the Clinical Trials Search Portal of the World Health Organization (January 2020). We checked the reference lists of all the trials identified. We also contacted those groups or individuals who may have completed relevant randomised trials in this area. Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 13 January 2020; date of the last search of the Cochrane Wounds Group Trials Register: 17 February 2017. SELECTION CRITERIA Randomised controlled trials of interventions for treating leg ulcers in people with sickle cell disease compared to placebo or an alternative treatment. DATA COLLECTION AND ANALYSIS Two authors independently selected studies for inclusion. All three authors independently assessed the risk of bias of the included studies and extracted data. We used GRADE to assess the quality of the evidence. MAIN RESULTS Six studies met the inclusion criteria (198 participants with 250 ulcers). Each trial investigated a different intervention and within this review we have grouped these as systemic pharmaceutical interventions (L-cartinine, arginine butyrate, isoxsuprine) and topical pharmaceutical interventions (Solcoseryl® cream, arginine-glycine-aspartic acid (RGD) peptide dressing and topical antibiotics). No trials on non-pharmaceutical interventions were included in the review. All trials had an overall unclear or high risk of bias, and drug companies sponsored four of them. We were unable to pool findings due to the heterogeneity in outcome definitions, and inconsistency between the units of randomisation and analysis. Three interventions reported on the change in ulcer size (arginine butyrate, RGD peptide, L-cartinine). Of these, only arginine butyrate showed a reduction of ulcer size compared with a control group, mean reduction -5.10 cm² (95% CI -9.65 to -0.55), but we are uncertain whether this reduces ulcer size compared to standard care alone as the certainty of the evidence has been assessed as very low. Three trials reported on complete leg ulcer closure (isoxsuprine, arginine butyrate, RGD peptide matrix; very low quality of evidence). None reported a clinical benefit. No trial reported on: the time to complete ulcer healing; ulcer-free survival following treatment for sickle cell leg ulcers; quality of life measures; incidence of amputation or harms. AUTHORS' CONCLUSIONS Given the very low quality of the evidence identified in this updated Cochrane Review we are uncertain whether any of the assessed pharmaceutical interventions reduce ulcer size or result in leg ulcer closure in treated participants compared to controls. However, this intervention was assessed as having a high risk of bias due to inadequacies in the single trial report. Other included studies were also assessed as having an unclear or high risk of bias. The harm profile of the all interventions remains inconclusive.
Collapse
Affiliation(s)
- Arturo J Martí-Carvajal
- Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE (Cochrane Ecuador), Quito, Ecuador
- School of Medicine, Universidad Francisco de Vitoria (Cochrane Madrid), Madrid, Spain
| | | | - Maria José Martinez-Zapata
- Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| |
Collapse
|
11
|
Nwagu MU, Omokhua GI. Treatment of recalcitrant chronic leg ulcer in a known sickle cell anaemia patient using honey and fresh hbaa red cell concentrate in a Nigerian secondary healthcare facility. Ann Afr Med 2020; 19:278-281. [PMID: 33243953 PMCID: PMC8015949 DOI: 10.4103/aam.aam_53_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Sickle hemoglobin (HbS) formed by the point mutation in the genetic code of beta-globin chain leading to valine substituting glutamic acid at position 6 of the beta-chain. The resultant sickle cell disease (SCD) characterized by occlusion of microvasculature by red blood cells is associated with multiple organ pathologies. One of such complications is chronic leg ulcers. We report a case of chronic leg ulcer, in a known sickle cell anemia patient, which did not respond to the wound dressing methods at the hospital's disposal. The ulcer was successfully treated using standard operative procedure (S.O.P) in wound care, applying local honey, and use of blood transfusion. EA was a 20-year-old university undergraduate who was admitted to April 2019 in Central Hospital Benin City with chronic leg ulcer of 1 year duration. She was also anemic with hemoglobin concentration of 3.0 g/dl (packed cell volume 15%). The wound was dressed with local honey, and anemia corrected with blood transfusion using concentrated red cells lacking the HbS trait. There was a progressive improvement in the healing of the ulcer with total closure after 4 months of treatment. Maintenance and follow-up measures were instituted to prevent reoccurrence. This report showed that honey has remarkable properties in promoting wound healing. Its usage in combination with transfusion of HbA red blood cells to manage chronic leg ulcers in SCD patients is advocated. However, this calls for further studies and research.
Collapse
|
12
|
Granja PD, Quintão SBM, Perondi F, de Lima RBF, Martins CLDM, Marques MA, de Oliveira JCP. Leg ulcers in sickle cell disease patients. J Vasc Bras 2020; 19:e20200054. [PMID: 34211517 PMCID: PMC8218003 DOI: 10.1590/1677-5449.200054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Leg ulcers are the most common cutaneous complication of sickle cell disease. These lesions occur mainly in homozygous forms, are slow to heal and often relapse, causing negative physical, emotional, and economic impacts. In this paper, we discuss the clinical presentation, diagnosis, and pathophysiology of sickle cell leg ulcers and their implications for treatment.
Collapse
Affiliation(s)
- Paula Dadalti Granja
- Departamento de Medicina Clínica - MMC, Faculdade de Medicina, Universidade Federal Fluminense - UFF, Niterói, RJ, Brasil
| | | | - Franciele Perondi
- Departamento de Medicina Clínica - MMC, Faculdade de Medicina, Universidade Federal Fluminense - UFF, Niterói, RJ, Brasil
| | | | | | - Marcos Arêas Marques
- Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, RJ, Brasil.,Hospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, RJ, Brasil
| | - Julio Cesar Peclat de Oliveira
- Hospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, RJ, Brasil.,Cirurgia Vascular, Universidade Federal do Rio de Janeiro - UFRJ, Rio de Janeiro, RJ, Brasil
| |
Collapse
|
13
|
Kaliyadan F, Alkhars AZ, Albaqshi AA, AlHajri HM, Albaqshi NK, Aldihnayn RM, Almarzooq ZY. Prevalence and Predictive Factors for Leg Ulcers in Sickle Cell Disease Patients in Saudi Arabia: A Cross-Sectional Observational Study. Cureus 2020; 12:e11280. [PMID: 33274155 PMCID: PMC7707884 DOI: 10.7759/cureus.11280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Introduction Saudi Arabia has a high prevalence of sickle cell disease (SCD). Leg ulceration is one of the complications associated with SCD. There is a gap in the literature in regard to the prevalence of leg ulcers among SCD patients in Saudi Arabia. Objectives The primary objective of this study was to evaluate the lifetime prevalence of leg ulcers in SCD patients in our population and to study the predictive factors of leg ulcers by using sociodemographic factors, clinical manifestations of SCD, and other relevant factors like hydroxyurea. Methods A cross-sectional study design was utilized. Data collection was done using an electronic survey to collect self-reported information for the prevalence of leg ulcers and possible associated factors. The survey was distributed using social media platforms. Chi-square test was used to test for the presence of an association between having leg ulcers and sociodemographic variables as well as SCD related history. Furthermore, binary logistic regression was utilized to determine factors predicting the incidence of leg ulcers among SCD. Results A total of 790 valid responses were included in the study. Among these, 646 were included in the analysis of leg ulcers prevalence. From them, 52 (8%) SCD patients reported a history of leg ulcers. The male to female ratio was (9.7% vs 7.2%). The age group most affected by leg ulcers was those older than 50 (16.7%). There was no significant association between a history of leg ulcers and sociodemographic variables. The only predictive factors for leg ulcers were having six to eight vaso-occlusive crises per month and having more than eight vaso-occlusive crises per month. Conclusion Leg ulcers among SCD patients in Saudi Arabia were considerably prevalent (8%). There was no statistically significant correlation between leg ulceration and sociodemographic variables. Leg ulcers were more likely in patients with a history of highly frequent vaso-occlusive crises. No association was found between the incidence of leg ulcers and other complications of sickle cell disease or hydroxyurea.
Collapse
Affiliation(s)
- Feroze Kaliyadan
- Dermatology, College of Medicine, King Faisal University, Al-Ahsa, SAU
| | - Ahmed Z Alkhars
- General Medicine and Surgery, College of Medicine, King Faisal University, Al-Ahsa, SAU
| | | | - Hajar M AlHajri
- Medicine, College of Medicine, King Faisal University, Al-Ahsa, SAU
| | - Norah K Albaqshi
- Medicine, College of Medicine, King Faisal University, Al-Ahsa, SAU
| | | | | |
Collapse
|
14
|
A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis. Ann Hematol 2020; 99:2073-2079. [PMID: 32377816 DOI: 10.1007/s00277-020-04057-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Accepted: 04/25/2020] [Indexed: 02/02/2023]
Abstract
Vasculopathy is a hallmark of sickle cell disease ultimately resulting in chronic end organ damage. Leg ulcer is one of its sequelae, occurring in ~ 5-10% of adult sickle cell patients. The majority of leg ulcer publications to date have emanated from single center cohort studies. As such, there are limited studies on the geographic distribution of leg ulcers and associated risk factors worldwide. The Consortium for the Advancement of Sickle Cell Research (CASiRe) was formed to improve the understanding of the different phenotypes of sickle cell disease patients living in different geographic locations around the world (USA, UK, Italy, Ghana). This cross-sectional cohort sub-study of 659 sickle cell patients aimed to determine the geographic distribution and risk factors associated with leg ulcers. The prevalence of leg ulcers was 10.3% and was associated with older age, SS genotype, male gender, and Ghanaian origin. In fact, the highest prevalence (18.6%) was observed in Ghana. Albuminuria, proteinuria, increased markers of hemolysis (lower hemoglobin, higher total bilirubin), lower oxygen saturation, and lower body mass index were also associated with leg ulceration. Overall, our study identified a predominance of leg ulcers within male hemoglobin SS patients living in sub-Saharan Africa with renal dysfunction and increased hemolysis.
Collapse
|
15
|
Ballas SK, Darbari DS. Review/overview of pain in sickle cell disease. Complement Ther Med 2020; 49:102327. [PMID: 32147066 DOI: 10.1016/j.ctim.2020.102327] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 01/22/2020] [Accepted: 01/22/2020] [Indexed: 12/28/2022] Open
Abstract
Sickle cell disease (SCD) is a highly complex inherited disorder of hemoglobin structure. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of the disease. Its manifestations could be acute, chronic, nociceptive, neuropathic that could occur singly or in various combinations. Pain continues to be the major factor of SCD phenotypic complications and the most common cause of admissions to the Emergency Department and/or the hospital. Although progress has been made in understanding the pathophysiology of SCD as well as in developing curative therapies such as hematopoietic stem cell transplantation and gene therapy, effective pain management continues to lag behind. Palliative therapies continue to be the major approach to the management of SCD and its complications. The advent of hydroxyurea made partial success in preventing the frequency of vaso-occlusive crises and l-glutamine awaits post-trial confirmation of benefits. The search for additional pharmacotherapeutic agents that could be used singly or in combination with hydroxyurea and/or l-glutamine awaits their dawn hopefully in the near future. The purpose of this review is to describe the various manifestations of SCD, their pathophysiology and their current management. Recent impressive advances in understanding the pathophysiology of pain promise the determination of agents that could replace or minimize the use of opioids.
Collapse
Affiliation(s)
- Samir K Ballas
- Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA, USA.
| | - Deepika S Darbari
- Division of Hematology, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC, USA
| |
Collapse
|
16
|
Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa. J Clin Med 2019; 8:jcm8122173. [PMID: 31835320 PMCID: PMC6947353 DOI: 10.3390/jcm8122173] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 12/03/2019] [Accepted: 12/04/2019] [Indexed: 02/02/2023] Open
Abstract
Sickle cell disease (SCD) prevalence has increased rapidly in Europe as a result of an increase in the life expectancy of these patients and the arrival of SCD migrants from Africa. The aim of our study was to compare the phenotypes of adult patients born in Sub-Saharan Africa (SSA) who migrated to France with those of patients with the same origin who were born in France. This single-center observational study compared the demographic, clinical and biological characteristics of SCD adult patients of SSA origin who were born in France or SSA. Data were collected from computerized medical charts. Groups were compared using multivariate logistic regression with adjustment for age, gender and type of SCD. Of the 323 SCD patients followed in our center, 235 were enrolled, including 111 patients born in France and 124 patients born in SSA. SCD genotypes were balanced between groups. Patients born in Africa were older (median age 32.1 (24.4-39) vs. 25.6 (22.1-30.5) years, p < 0.001) and more often women (n = 75 (60.5%) vs. 48 (43.2%), p = 0.008). The median age at arrival in France was 18 years (13-23). The median height was lower among patients born in SSA (169 (163-175) vs. 174.5 cm (168-179), p < 0.001). Over their lifetimes, patients born in France had more acute chest syndromes (median number 2 (1-4) vs. 1 (0-3), p = 0.002), with the first episode occurring earlier (19 (11.6-22.3) vs. 24 (18.4-29.5) years, p < 0.007), and were admitted to intensive care units more often (53.3% vs. 34.9%, p = 0.006). This difference was more pronounced in the SS/Sβ0 population. Conversely, patients born in SSA had more skin ulcers (19.4% vs. 6.3%, p = 0.03). No significant differences were found in social and occupational insertion or other complications between the two groups. Patients born in SSA had a less severe disease phenotype regardless of their age than those born in France. This difference could be related to a survival bias occurring in Africa during childhood and migration to Europe that selected the least severe phenotypes.
Collapse
|
17
|
Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Schols EM, Philipsen JNJ, Tamminga RYJ, van Draat KF, Nur E, Cnossen MH. Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Rev 2019; 37:100580. [PMID: 31128863 DOI: 10.1016/j.blre.2019.05.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 05/17/2019] [Accepted: 05/17/2019] [Indexed: 01/12/2023]
Abstract
Sickle cell disease is an autosomal recessive, multisystem disorder, characterised by chronic haemolytic anaemia, painful episodes of vaso-occlusion, progressive organ failure and a reduced life expectancy. Sickle cell disease is the most common monogenetic disease, with millions affected worldwide. In well-resourced countries, comprehensive care programs have increased life expectancy of sickle cell disease patients, with almost all infants surviving into adulthood. Therapeutic options for sickle cell disease patients are however, still scarce. Predictors of sickle cell disease severity and a better understanding of pathophysiology and (epi)genetic modifiers are warranted and could lead to more precise management and treatment. This review provides an extensive summary of the pathophysiology and management of sickle cell disease and encompasses the characteristics, complications and current and future treatment options of the disease.
Collapse
Affiliation(s)
- M E Houwing
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - P J de Pagter
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - E J van Beers
- Department of Internal Medicine and Dermatology, Van Creveldkliniek, University Medical Center Utrecht, Internal mail no C.01.412, 3508, GA, Utrecht, the Netherlands.
| | - B J Biemond
- Department of Internal Medicine and Clinical Haematology, Amsterdam University Medical Centers, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
| | - E Rettenbacher
- Department of Paediatric Haematology, Radboud University Medical Center - Amalia Children's Hospital, Geert Grooteplein Zuid 10, 6500, HB, Nijmegen, the Netherlands.
| | - A W Rijneveld
- Department of Haematology, Erasmus University Medical Center, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - E M Schols
- Department of Haematology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, the Netherlands.
| | - J N J Philipsen
- Department of Cell Biology, Erasmus University Medical Center, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - R Y J Tamminga
- Department of Paediatric Oncology and Haematology, University Medical Center Groningen - Beatrix Children's Hospital, Postbus 30001, 9700, RB, Groningen, the Netherlands..
| | - K Fijn van Draat
- Department of Paediatric Haematology, Amsterdam University Medical Centers - Emma Children's Hospital, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Department of Plasma Proteins, Sanquin Research, the Netherlands.
| | - E Nur
- Department of Internal Medicine and Clinical Haematology, Amsterdam University Medical Centers, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
| | - M H Cnossen
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| |
Collapse
|
18
|
Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, Cartwright D. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2018; 21:27-32. [PMID: 29304937 DOI: 10.1016/j.jval.2017.07.007] [Citation(s) in RCA: 597] [Impact Index Per Article: 99.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 06/07/2017] [Accepted: 07/16/2017] [Indexed: 05/22/2023]
Abstract
OBJECTIVE The aim of this study was to determine the cost of chronic wound care for Medicare beneficiaries in aggregate, by wound type and by setting. METHODS This retrospective analysis of the Medicare 5% Limited Data Set for calendar year 2014 included beneficiaries who experienced episodes of care for one or more of the following: arterial ulcers, chronic ulcers, diabetic foot ulcers, diabetic infections, pressure ulcers, skin disorders, skin infections, surgical wounds, surgical infections, traumatic wounds, venous ulcers, or venous infections. The main outcomes were the prevalence of each wound type, Medicare expenditure for each wound type and aggregate, and expenditure by type of service. RESULTS Nearly 15% of Medicare beneficiaries (8.2 million) had at least one type of wound or infection (not pneumonia). Surgical infections were the largest prevalence category (4.0%), followed by diabetic infections (3.4%). Total Medicare spending estimates for all wound types ranged from $28.1 to $96.8 billion. Including infection costs, the most expensive estimates were for surgical wounds ($11.7, $13.1, and $38.3 billion), followed by diabetic foot ulcers ($6.2, $6.9, and $18.7 billion,). The highest cost estimates in regard to site of service were for hospital outpatients ($9.9-$35.8 billion), followed by hospital inpatients ($5.0-$24.3 billion). CONCLUSIONS Medicare expenditures related to wound care are far greater than previously recognized, with care occurring largely in outpatient settings. The data could be used to develop more appropriate quality measures and reimbursement models, which are needed for better health outcomes and smarter spending for this growing population.
Collapse
Affiliation(s)
- Samuel R Nussbaum
- Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA
| | | | - Caroline E Fife
- Baylor College of Medicine, Houston, TX, USA; CHI St. Lukes Hospital, The Woodlands, TX, USA; The US Wound Registry, The Woodlands, TX, USA
| | - Joan DaVanzo
- Dobson/DaVanzo & Associates LLC, Vienna, VA, USA
| | | | | | | |
Collapse
|
19
|
Umeh NI, Ajegba B, Buscetta AJ, Abdallah KE, Minniti CP, Bonham VL. The psychosocial impact of leg ulcers in patients with sickle cell disease: I don't want them to know my little secret. PLoS One 2017; 12:e0186270. [PMID: 29045487 PMCID: PMC5646800 DOI: 10.1371/journal.pone.0186270] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Accepted: 09/28/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Sickle cell disease (SCD) impacts millions of individuals worldwide and more than 100,000 people in the United States. Leg ulcers are the most common cutaneous manifestation of SCD. The health status of individuals living with chronic leg ulcers is not only influenced by clinical manifestations such as pain duration and intensity, but also by psychosocial factors. Garnering insights into the psychosocial impact can provide a more holistic view of their influence on quality of life. METHODS Semi-structured interviews were conducted with participants living with active SCD-associated leg ulcers or with a history of ulcers. Subjects were recruited from an ongoing study (INSIGHTS, Clin Trial.Gov NCT02156102) and consented to this qualitative phase of the study. Five areas were explored: leg ulcer pain, physical function, social-isolation, social relationships and religious support. Data was collected from 20 individuals during these interviews and a thematic analysis was performed and reported. RESULTS Twenty participants with a mean age of 42.4 (SD ± 11.1years) were included in the study. Major themes identified included:1) pain (acute and chronic); 2) compromised physical function as demonstrated by decreased ability to walk, run, and play sports; 3) social isolation from activities either by others or self-induced as a means of avoiding certain emotions, such as embarrassment; 4) social relationships (family support and social network); 5) support and comfort through their religion or spirituality. CONCLUSIONS SCD patients with leg ulcers expressed that they experience social isolation, intense and frequent ulcer pain, and difficulty in physical function. SCD-associated leg ulcers have been studied from a clinical approach, but the psychosocial factors investigated in this study informs how quality of life is impacted by the leg ulcers.
Collapse
Affiliation(s)
- Nkeiruka I. Umeh
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
- Albany Medical College, Albany, New York, United States of America
| | - Brittany Ajegba
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
- Michigan State University, College of Human Medicine, East Lansing, Michigan, United States of America
| | - Ashley J. Buscetta
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Khadijah E. Abdallah
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Caterina P. Minniti
- Montefiore Medical Center, Division of Hematology, Sickle Cell Center, Bronx, New York City, New York, United States of America
| | - Vence L. Bonham
- Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
- * E-mail:
| |
Collapse
|
20
|
AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. THE JOURNAL OF PAIN 2017; 18:490-498. [DOI: 10.1016/j.jpain.2016.12.016] [Citation(s) in RCA: 112] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Revised: 12/14/2016] [Accepted: 12/20/2016] [Indexed: 12/11/2022]
|
21
|
Martins MMF, Teixeira MCP. Análise dos gastos das internações hospitalares por anemia falciforme no estado da Bahia. ACTA ACUST UNITED AC 2017. [DOI: 10.1590/1414-462x201700010209] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Resumo Introdução A anemia falciforme é uma doença com alterações genéticas que afeta principalmente a população negra. No curso da doença, surgem diversas complicações clínicas, levando à necessidade de repetidas internações hospitalares. Objetivo Descrever os gastos das internações hospitalares por complicações da anemia falciforme no estado da Bahia, no período de 2008 a 2014. Métodos Estudo descritivo, a partir de dados secundários. A população do estudo foi composta por pacientes internados com diagnóstico de anemia falciforme. Para coleta e análise dos dados, utilizou-se a divisão por Macrorregião de Saúde do estado da Bahia. Resultados Foram analisadas 8.103 internações do SIH-SUS. Predomínio do sexo masculino e faixa etária de 5-14 anos. A Macrorregião de Saúde Leste obteve o maior número de ocorrências de internações por anemia falciforme (33,4%) com maior gasto total; a Macrorregião Sul apresentou maior coeficiente de hospitalização; e a Macrorregião Extremo Sul apresentou a maior taxa de letalidade. As Macrorregiões Leste e Sul são as que abrigam os maiores volumes de gastos, 40,5% e 18,9%, respectivamente. Conclusão O estudo permite conhecer o perfil de internações hospitalares por anemia falciforme e ter uma ideia dos custos hospitalares através das internações pela referida doença no período em estudo.
Collapse
|
22
|
Meneses JVL, Fortuna V, de Souza ES, Daltro GC, Meyer R, Minniti CP, Borojevic R. Autologous stem cell-based therapy for sickle cell leg ulcer: a pilot study. Br J Haematol 2016; 175:949-955. [DOI: 10.1111/bjh.14326] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 07/18/2016] [Indexed: 02/03/2023]
Affiliation(s)
| | - Vitor Fortuna
- Health Science Institute; Federal University of Bahia; Salvador BA Brazil
| | | | | | - Roberto Meyer
- Health Science Institute; Federal University of Bahia; Salvador BA Brazil
| | - Caterina P. Minniti
- Division of Hematology-Oncology; Department of Medicine; Montefiore Medical Center; Bronx NY USA
| | - Radovan Borojevic
- Petrópolis School of Medicine/Arthur de Sá Earp Faculties; Petrópolis RJ Brazil
| |
Collapse
|
23
|
Yousry SM, Ellithy HN, Shahin GH. Endothelial nitric oxide synthase gene polymorphisms and the risk of vasculopathy in sickle cell disease. ACTA ACUST UNITED AC 2016; 21:359-67. [PMID: 26903375 DOI: 10.1080/10245332.2016.1142710] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
BACKGROUND Sickle cell disease (SCD) is one of the major health problems in many parts of the world. SCD is characterized by multisystem complications with marked variability in its severity between patients, probably linked to nitric oxide (NO). Endothelial nitric oxide synthase (eNOS) enzyme which is responsible for NO synthesis may be implicated in SCD pathophysiology. AIM OF THE STUDY To explore the possible association between the eNOS gene polymorphisms and severity of SCD. Furthermore, we examined the genomic diversity of these polymorphisms in SCD patients. METHODS We genotyped 100 SCD patients and 80 controls were genotyped for eNOS 4a/b and eNOS 786T>C polymorphisms, using allele-specific polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism assay, respectively. Polymorphisms were analyzed in relation to severity of SCD manifestations. RESULTS The homozygous mutant eNOS-786T>T genotype was significantly associated with high risk of acute chest syndrome (ACS). The wild-type eNOS-4a/4b genotype was protective against vaso-occlusive crisis (VOC) and pulmonary hypertension (PHTN). The mutant homozygous haplotype (C -4a) was significantly associated with the risk of ACS, VOC, and PHTN. CONCLUSION eNOS intron 4 and eNOS T>C gene polymorphisms may be used as a genetic marker of prognostic value in SCD, as they are associated with unfavorable clinical outcomes.
Collapse
Affiliation(s)
- Sherif M Yousry
- a Clinical Pathology, Faculty of Medicine , Cairo University , Egypt
| | - Hend N Ellithy
- b Clinical Hematology-Internal Medicine Department, Faculty of Medicine , Cairo University , Egypt
| | - Gehan H Shahin
- a Clinical Pathology, Faculty of Medicine , Cairo University , Egypt
| |
Collapse
|
24
|
Ndiaye M, Niang S, Diop A, Diallo M, Diaz K, Ly F, Dioussé P, Diatta B, Seck N, Diallo S, Ndiaye M, Diadie S, Dieng M, Kane A. Ulcères de jambe au cours de la drépanocytose : étude rétrospective de 40 cas. Ann Dermatol Venereol 2016; 143:103-7. [DOI: 10.1016/j.annder.2015.12.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 10/07/2015] [Accepted: 12/01/2015] [Indexed: 11/25/2022]
|
25
|
Minniti CP, Kato GJ. Critical Reviews: How we treat sickle cell patients with leg ulcers. Am J Hematol 2016; 91:22-30. [PMID: 26257201 DOI: 10.1002/ajh.24134] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 07/23/2015] [Indexed: 12/22/2022]
Abstract
The past five decades have seen an improvement in the mortality and morbidity of sickle cell disease (SCD) because of prophylaxis against infectious complications, improved and expanded red cell transfusions, implementation of hydroxyurea therapy, and advances in supportive care. Now that the majority of patients in the western hemisphere reaches adulthood, end organ diseases are frequent, which include vasculopathic complications such as chronic leg ulcers. The management of patients with leg ulcers requires the hematologist to lead a team of health care professionals, and investigates the presence of associated, but potentially still occult signs of vasculopathy, such as pulmonary hypertension, renal disease, priapism and retinopathy. These complications may be asynchronous, and long term careful screening is indicated, in order to ensure early diagnosis and intervention. It is crucial to address both the immediate consequences of pain, infection and disability, and long term effects on quality of life, employment and stigma associated with chronic ulceration. Recent insights into their pathophysiology may have practical implications. We propose a holistic approach to the management of patients' physical and emotional problems and mechanisms of ulcers formation and delayed healing. An overview of topical and systemic therapies for chronic ulcers is given, with the understanding that wound care therapy is best left to the wound specialists, medical and surgical, with whom the hematologist must keep an open line of communication. In the absence of evidence-based guidelines, our opinion is based on both a critical review of the literature and our personal clinical and research experience.
Collapse
Affiliation(s)
- Caterina P. Minniti
- Division of Hematology-Oncology, Department of Medicine; Montefiore Medical Center; Bronx New York
| | - Gregory J. Kato
- Division of Hematology-Oncology, Department of Medicine and the Heart, Lung; Blood and Vascular Medicine Institute, University of Pittsburgh; Pittsburgh Pennsylvania
| |
Collapse
|
26
|
Altman IA, Kleinfelder RE, Quigley JG, Ennis WJ, Minniti CP. A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease. Int Wound J 2015; 13:1315-1324. [PMID: 26537664 DOI: 10.1111/iwj.12522] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 09/20/2015] [Indexed: 12/31/2022] Open
Abstract
Sickle cell leg ulcers (SCLUs) are a common complication of sickle cell disease (SCD). Patients who develop ulcers appear to have a more severe haemolysis-associated vasculopathy than individuals who do not develop them, and manifest other complications such as priapism and pulmonary hypertension. SCLUs are slow to heal and often recur, affecting both the emotional and physical well-being of patients. Here we summarise what is known about the pathophysiology of SCLUs, describe available treatment options and propose a treatment algorithm.
Collapse
Affiliation(s)
- Igor A Altman
- Department of Surgery, Section of Wound Healing and Tissue Repair, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA
| | - Raymond E Kleinfelder
- Traditional Rotating Internship, Genesys Regional Medical Center, Grand Blanc, MI, USA
| | - John G Quigley
- Department of Hematology and Medical Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA
| | - William J Ennis
- Department of Surgery, Section of Wound Healing and Tissue Repair, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA
| | - Caterina P Minniti
- Department of Oncology, Division of Hematology, Sickle Cell Center, Montefiore Medical Center, Bronx, NY, USA
| |
Collapse
|
27
|
Martí-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database Syst Rev 2014; 2014:CD008394. [PMID: 25485858 PMCID: PMC7175837 DOI: 10.1002/14651858.cd008394.pub3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND The frequency of skin ulceration makes it an important contributor to the morbidity burden in people with sickle cell disease. Many treatment options are available to the healthcare professional, although it is uncertain which treatments have been assessed for effectiveness in people with sickle cell disease. OBJECTIVES To assess the clinical effectiveness and safety of interventions for treating leg ulcers in people with sickle cell disease. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register.We searched LILACS (1982 to August 2012), the African Index Medicus (up to August 2012), ISI Web of Knowledge (1985 to August 2012), and the Clinical Trials Search Portal of the World Health Organization (August 2012). We checked the reference lists of all the trials identified. We also contacted those groups or individuals who may have completed relevant randomised trials in this area.Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 21 July 2014; date of the last search of the Cochrane Wounds Group Trials Register: 18 September 2014. SELECTION CRITERIA Randomised controlled trials of interventions for treating leg ulcers in people with sickle cell disease compared to placebo or an alternative treatment. DATA COLLECTION AND ANALYSIS Two authors independently selected studies for inclusion. All three authors independently assessed the risk of bias of the included studies and extracted data. MAIN RESULTS Six studies met the inclusion criteria (198 participants with 250 ulcers). Each trial investigated a different intervention and within this review we have grouped these as systemic pharmaceutical interventions (L-cartinine, arginine butyrate, isoxsuprine) and topical pharmaceutical interventions (Solcoseryl(®) cream, RGD peptide dressing, topical antibiotics). Three interventions reported on the change in ulcer size (arginine butyrate, RGD peptide, L-cartinine). Of these, RGD peptide matrix significantly reduced ulcer size compared with a control group, mean reduction 6.60cm(2) (95% CI 5.51 to 7.69; very low quality of evidence). Three trials reported on the incidence of complete closure (isoxsuprine, arginine butyrate, RGD peptide matrix; ranging between low and very low quality of evidence). None reported a significant effect. No trial reported on: the time to complete ulcer healing; ulcer-free survival following treatment for sickle cell leg ulcers; quality of life measures; or incidence of amputation. There was no reported information on the safety of these interventions. AUTHORS' CONCLUSIONS There is evidence that a topical intervention (RGD peptide matrix) reduced ulcer size in treated participants compared to controls. This evidence of efficacy is limited by the generally high risk of bias associated with these reports.We planned to analyse results according to general groups: pharmaceutical interventions (systemic and topical); and non-pharmaceutical interventions (surgical and non-surgical). However, we were unable to pool findings due to the heterogeneity in outcome definitions, and inconsistency between the unit of randomisation and the unit of analysis. This heterogeneity, along with a paucity of identified trials, prevented us performing any meta-analyses.This Cochrane review provides some evidence for the effectiveness of one topical intervention - RGD peptide matrix. However, this intervention was assessed as having a high risk of bias due to inadequacies in the single trial report. Other included studies were also assessed as having a high risk of bias. We recommend that readers interpret the trial results with caution. The safety profile of the all interventions was inconclusive.
Collapse
|
28
|
Minniti CP, Gorbach AM, Xu D, Hon YY, Delaney KM, Seidel M, Malik N, Peters-Lawrence M, Cantilena C, Nichols JS, Mendelsohn L, Conrey A, Grimes G, Kato GJ. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. LANCET HAEMATOLOGY 2014; 1:e95-e103. [PMID: 25938131 DOI: 10.1016/s2352-3026(14)00019-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Well-tolerated and effective treatments are needed for chronic leg ulcers in sickle cell anaemia. Topical sodium nitrite, a known nitric oxide donor, enhances blood flow in ulcers and has known bacteriostatic effects. We aimed to assess the safety, tolerability, and pharmacokinetics of topical sodium nitrite in patients with sickle cell disease and chronic leg ulcers. METHODS We enrolled adult patients from an ambulatory clinic at the National Institutes of Health (Bethesda, MD, USA) with sickle cell anaemia with leg ulcers (with a surface area of 2.5-100 cm2) persisting for at least 4 weeks into a safety and tolerability phase 1 dose-escalation trial of topical sodium nitrite. Increasing concentrations of sodium nitrite cream were applied twice weekly for 4 weeks to one ulcer per patient at five dose levels (0.5%, 1%, 1.5%, 1.8%, and 2%). The primary endpoints were safety and tolerability, with secondary endpoints of pharmacokinetics, blood flow, and wound healing. Pain relief was analysed post hoc. Endpoints were analysed over time for the whole study population and according to dose level. This study is registered with ClinicalTrials.gov, number NCT01316796. FINDINGS Between April 4, 2011, and March 19, 2013, we enrolled 18 adult patients with sickle cell anaemia and leg ulcers into our trial. We assigned three patients into each cohort, and each cohort was treated with a different concentration of sodium nitrite cream (cohort 1: 0.5%, cohort 2: 1.0%, cohort 3: 1.5%, and cohort 4: 2.0%). Patients were not enrolled into the next cohort dose until we were able to establish that no dose-limiting toxicities were observed. An additional six patients were enrolled to cohort 3a: 1.8%, after two patients in cohort 4 had asymptomatic drops in diastolic blood pressure. No grade 3-4 adverse events were observed, and there were no serious adverse events or dose-limiting side-effects. Pharmacokinetic analysis showed that systemic absorption of sodium nitrite was very low. Application of topical sodium nitrite was associated with a significant increase in peri-wound cutaneous blood flow measured by laser speckle contrast imaging (p=0.0002), corroborated by increased peri-wound skin temperature by infrared thermography (p=0.0119). We recorded a dose-dependent decrease in leg ulcer size (p=0.0012) and pain (p<0.0001). Ulcers healed completely in three patients who received the highest concentrations of topical sodium nitrite (the 1.8% and 2% cream). In our post-hoc analysis of pain, brief pain inventory scores improved in pain severity (p=0.0048) and pain interference (p=0.0013). INTERPRETATION Our results indicate that topical sodium nitrite 2% cream is suitable for additional clinical trials in adults with sickle cell anaemia to promote healing of leg ulcers. FUNDING National Heart, Lung and Blood Institute Division of Intramural Research (National Institutes of Health).
Collapse
Affiliation(s)
- Caterina P Minniti
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Alexander M Gorbach
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Dihua Xu
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Yuen Yi Hon
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Kara-Marie Delaney
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Miles Seidel
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Nitin Malik
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Marlene Peters-Lawrence
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Carly Cantilena
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - James S Nichols
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Laurel Mendelsohn
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Anna Conrey
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - George Grimes
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Gregory J Kato
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| |
Collapse
|
29
|
Clinical findings associated with homozygous sickle cell disease in the Barbadian population--do we need a national SCD registry? BMC Res Notes 2014; 7:102. [PMID: 24558976 PMCID: PMC3936843 DOI: 10.1186/1756-0500-7-102] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Accepted: 02/18/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Comprehensive care in homozygous sickle cell disease (HbSS) entails universal neonatal screening and subsequent monitoring of identified patients, a process which has been streamlined in the neighbouring island of Jamaica. In preparation for a similar undertaking in Barbados, we have developed a database of persons with known HbSS, and have piloted processes for documenting clinical manifestations. We now present a brief clinical profile of these findings with comparisons to the Jamaican cohort. METHODS HbSS participants were recruited from clinics and support groups. A history of select clinical symptoms was taken and blood and urine samples and echocardiograms were analysed. A re-analysis of data from a previous birth cohort was completed. RESULTS Forty-eight persons participated (32 F/16 M); age range 10-62 yrs. 94% had a history of ever having a painful crisis. In the past year, 44% of participants had at least one crisis. There were >69 crises in 21 individuals; 61% were self-managed at home and the majority of the others were treated and discharged from hospital; few were admitted. The prevalence of chronic leg ulceration was 27%. Forty-two persons had urinalysis, 44% were diagnosed with albuminuria (urinary protein/creatinine ratio ≥30 mg/g). Thirty-two participants had echocardiography, 28% had a TRJV ≥ 2.5 m/s. Re-analysis of the incidence study revealed a sickle gene frequency (95% CI) of 2.01% (0.24 to 7.21). CONCLUSION Although we share a common ancestry, it is thought that HbSS is less common and less severe in Barbados compared to Jamaica. The Jamaican studies reported a sickle gene frequency of 3.15 (2.81 to 3.52); the prevalence of chronic leg ulcers and albuminuria was 29.5% and 42.5% respectively. These comparisons suggest that our initial thoughts may be speculative and that HbSS may be an underestimated clinical problem in Barbados. A prospective neonatal screening programme combined with centralized, routine monitoring of HbSS morbidity and outcomes will definitively answer this question and will improve the evidence-based care and management of HbSS in Barbados.
Collapse
|
30
|
Evaluation of Th17 related cytokines associated with clinical and laboratorial parameters in sickle cell anemia patients with leg ulcers. Cytokine 2014; 65:143-7. [DOI: 10.1016/j.cyto.2013.11.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 11/18/2013] [Accepted: 11/24/2013] [Indexed: 02/03/2023]
|
31
|
Minniti CP, Delaney KMH, Gorbach AM, Xu D, Lee CCR, Malik N, Koroulakis A, Antalek M, Maivelett J, Peters-Lawrence M, Novelli EM, Lanzkron SM, Axelrod KC, Kato GJ. Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. Am J Hematol 2014; 89:1-6. [PMID: 23963836 DOI: 10.1002/ajh.23571] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 08/09/2013] [Accepted: 08/13/2013] [Indexed: 12/15/2022]
Abstract
Chronic leg ulcers are frequent and debilitating complications of sickle cell anemia. Inadequate blood supply has been postulated to be an important factor in their occurrence and delayed healing. Little is known about their microcirculatory and histopathological changes. We evaluated the microcirculation of lower extremity ulcers with laser speckle contrast imaging and infrared thermography and obtained clinical and laboratory characteristics in 18 adults with sickle cell anemia and chronic leg ulcers. Skin biopsies were obtained in four subjects. Subjects had markers of severe disease, anemia, high degree of hemolysis, inflammation, and thrombophilia. The highest blood flow was present in the ulcer bed, progressively less in the immediate periwound area, and an unaffected control skin area in the same extremity. Microscopic examination showed evidence of venostasis, inflammation, and vasculopathy. Blood vessels were increased in number, had activated endothelium and evidence of thrombosis/recanalization. High blood flow may be due to chronic inflammation, cutaneous vasodilatation, venostasis, and in situ thrombosis. These changes in skin microcirculation are similar to chronic venous ulcers in the non-sickle cell disease (SCD) population, thus suggesting that leg ulcers may be another end-organ complication with endothelial dysfunction that appears in patients with SCD at a younger age and with higher frequency than in the general population.
Collapse
Affiliation(s)
| | | | - Alexander M. Gorbach
- Infrared Imaging & Thermometry Unit; NIBIB, National Institutes of Health; Bethesda Maryland
| | - Dihua Xu
- Office of Biostatistics Research; NHLBI, National Institutes of Health; Bethesda Maryland
| | | | - Nitin Malik
- Infrared Imaging & Thermometry Unit; NIBIB, National Institutes of Health; Bethesda Maryland
| | - Antony Koroulakis
- Infrared Imaging & Thermometry Unit; NIBIB, National Institutes of Health; Bethesda Maryland
| | - Matthew Antalek
- Infrared Imaging & Thermometry Unit; NIBIB, National Institutes of Health; Bethesda Maryland
| | - Jordan Maivelett
- Infrared Imaging & Thermometry Unit; NIBIB, National Institutes of Health; Bethesda Maryland
| | | | - Enrico M. Novelli
- Division of Hematology/Oncology; UPMC Cancer Pavilion; Pittsburgh Pennsylvania
| | - Sophie M. Lanzkron
- Division of Hematology, Department of Medicine; Johns Hopkins University School of Medicine; Baltimore Maryland
| | - Karen C. Axelrod
- Nursing and Patient Care Services; National Institutes of Health; Bethesda Maryland
| | - Gregory J. Kato
- Hematology Branch; NHLBI, National Institutes of Health; Bethesda Maryland
| |
Collapse
|
32
|
de Oliveira Filho RA, Silva GJ, de Farias Domingos I, Hatzlhofer BLD, da Silva Araújo A, de Lima Filho JL, Bezerra MAC, Martins DBG, de Araújo RFF. Association between the genetic polymorphisms of glutathione S-transferase (GSTM1 and GSTT1) and the clinical manifestations in sickle cell anemia. Blood Cells Mol Dis 2013; 51:76-9. [DOI: 10.1016/j.bcmd.2013.03.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Revised: 03/06/2013] [Accepted: 03/07/2013] [Indexed: 01/23/2023]
|
33
|
Martí-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database Syst Rev 2012; 11:CD008394. [PMID: 23152256 DOI: 10.1002/14651858.cd008394.pub2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND The frequency of skin ulceration makes it an important contributor to the morbidity burden in people with sickle cell disease. Many treatment options are available to the healthcare professional, although it is uncertain which treatments have been assessed for effectiveness in people with sickle cell disease. OBJECTIVES To assess the clinical effectiveness and safety of interventions for treating leg ulcers in people with sickle cell disease. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register.We searched LILACS (1982 to August 2012), the African Index Medicus (up to August 2012), ISI Web of Knowledge (1985 to August 2012), and the Clinical Trials Search Portal of the World Health Organization (August 2012). We checked the reference lists of all the trials identified. We also contacted those groups or individuals who may have completed relevant randomised trials in this area.Date of the last search of the Group's Haemoglobinopathies Trials Register: 25 May 2012. SELECTION CRITERIA Randomised controlled trials of interventions for treating leg ulcers in people with sickle cell disease compared to placebo or an alternative treatment. DATA COLLECTION AND ANALYSIS Two authors independently selected studies for inclusion. All three authors independently assessed the risk of bias of the included studies and extracted data. MAIN RESULTS Six studies met the inclusion criteria (198 participants with 250 ulcers). Each trial investigated a different intervention and within this review we have grouped these as systemic pharmaceutical interventions (L-cartinine, arginine butyrate, isoxsuprine) and topical pharmaceutical interventions (Solcoseryl(®) cream, RGD peptide dressing, topical antibiotics). Three interventions reported on the change in ulcer size (arginine butyrate, RGD peptide, L-cartinine). Of these, RGD peptide matrix significantly reduced ulcer size compared with a control group, mean reduction 6.60cm(2) (95% CI 5.51 to 7.69). Three trials reported on the incidence of complete closure (isoxsuprine, arginine butyrate, RGD peptide matrix). None reported a significant effect. No trial reported on: the time to complete ulcer healing; ulcer-free survival following treatment for sickle cell leg ulcers; quality of life measures; or incidence of amputation. There was no reported information on the safety of these interventions. AUTHORS' CONCLUSIONS There is evidence that a topical intervention (RGD peptide matrix) reduced ulcer size in treated participants compared to controls. This evidence of efficacy is limited by the generally high risk of bias associated with these reports.We planned to analyse results according to general groups: pharmaceutical interventions (systemic and topical); and non-pharmaceutical interventions (surgical and non-surgical). However, we were unable to pool findings due to the heterogeneity in outcome definitions, and inconsistency between the unit of randomisation and the unit of analysis. This heterogeneity, along with a paucity of identified trials, prevented us performing any meta-analyses.This Cochrane review provides some evidence for the effectiveness of one topical intervention - RGD peptide matrix. However, this intervention was assessed as having a high risk of bias due to inadequacies in the single trial report. Other included studies were also assessed as having a high risk of bias. We recommend that readers interpret the trial results with caution. The safety profile of the all interventions was inconclusive.
Collapse
Affiliation(s)
- Arturo J Martí-Carvajal
- Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador.
| | | | | |
Collapse
|
34
|
Vasconcelos A, Prior AR, Ferrão A, Morais A. An adolescent with sickle cell anaemia experiencing disease-related complications: priapism and leg ulcer--a management challenge. BMJ Case Rep 2012; 2012:bcr.11.2011.5146. [PMID: 22605005 DOI: 10.1136/bcr.11.2011.5146] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Sickle-cell anaemia (SCA) is a multi-system disease, associated with episodes of acute illness and progressive organ damage. Disease severity shows substantial variation and it is often a burden for adolescents. Complications such as leg ulcer and priapism have a significant impact on quality of life. There are still no definitive treatment guidelines available. Considering the embarrassing nature of priapism and the dire consequences for erectile dysfunction, it is important to inform patients, parents and providers about the relationship of SCA to prolonged painful erections. This article will review the pathophysiology and treatment options of SCA focusing the complications of leg ulcers, priapism, cholelithiasis and retinopathy. The case study of a 14-year-old boy is used to present a management challenge of multiple SCA-related complications.
Collapse
Affiliation(s)
- Alexandra Vasconcelos
- Paediatrics Department, Hospital Professor Doutor Fernando Fonseca, Lisboa, Portugal.
| | | | | | | |
Collapse
|
35
|
Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. Am J Hematol 2010; 85:831-3. [PMID: 20872960 DOI: 10.1002/ajh.21838] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Sickle cell disease is a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction. The manifestations of this disease are protean.Among them, leg ulcers represent a particularly disabling and chronic complication, often associated with a more severe clinical course.Despite the fact that this complication has been recognized since the early times of SCD, there has been little improvement in the efficacy of its management and clinical outcome over the past 100 years. Recently, vasculopathic abnormalities involving abnormal vascular tone and activated, adhesive endothelium have been recognized as another pathway to end organ damage in sickle cell disease. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated with hemolytic severity, and reported in other severe hemolytic disorders. The authors present the proceedings from the Educational Session on Chronic leg ulcers in Sickle cell disease, held during the 4th Annual Sickle Cell Disease Research and Educational Symposium, on February 17, 2010 in Fort Lauderdale, Fla.
Collapse
Affiliation(s)
- Caterina P Minniti
- Pulmonary Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | | | | | |
Collapse
|
36
|
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2009; 115:2354-63. [PMID: 19903897 DOI: 10.1182/blood-2009-05-221333] [Citation(s) in RCA: 296] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The aim of this prospective study was to evaluate the long-term efficacy and safety of hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/beta(0)-thal, and 165 with HbS/beta(+)-thal participated in this trial. HU was administered to 131 patients, whereas 199 patients were conventionally treated. The median follow-up period was 8 years for HU patients and 5 years for non-HU patients. HU produced a dramatic reduction in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome. The probability of 10-year survival was 86% and 65% for HU and non-HU patients, respectively (P = .001), although HU patients had more severe forms of SCD. The 10-year probability of survival for HbS/HbS, HbS/beta (0)-thal, and HbS/IVSI-110 patients was 100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and 66%, for non-HU patients. The multivariate analysis showed that fetal hemoglobin values at baseline and percentage change of lactate dehydrogenase between baseline and 6 months were independently predicted for survival in the HU group. These results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients.
Collapse
|
37
|
Conran N, Costa FF. Hemoglobin disorders and endothelial cell interactions. Clin Biochem 2009; 42:1824-38. [PMID: 19580799 DOI: 10.1016/j.clinbiochem.2009.06.024] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2009] [Accepted: 06/20/2009] [Indexed: 11/15/2022]
Abstract
Endothelial damage and inflammation make a significant contribution to the pathophysiology of sickle cell disease (SCD) and the beta-thalassemia syndromes. Endothelial dysfunction and ensuing vasculopathy are implicated in pulmonary hypertension in the hemoglobinopathies and endothelial activation and endothelial-blood cell adhesion, accompanied by inflammatory processes and oxidative stress, are imperative to the vaso-occlusive process in SCD. Herein, we discuss the role that the endothelium plays in all of these processes and the effect that genetic modifiers and hydroxyurea therapy may have upon endothelial interactions. Therapies targeting the endothelium and endothelial interactions may represent a promising approach for treating these diseases.
Collapse
Affiliation(s)
- Nicola Conran
- Hematology and Hemotherapy Centre, School of Medical Sciences, University of Campinas - UNICAMP, Brazil.
| | | |
Collapse
|
38
|
Abstract
BACKGROUND The cause of chronic leg ulcer (CLU) in patients with sickle cell anemia (SCA) is unknown; it has been attributed to hypercoagulability associated with the disease. Recently, it has been suggested that a subset of SCA patients may be prone to developing CLU and that hemolysis may be an underlying factor in the development of CLU. The lupus anticoagulant (LA) is an antiphospholipid antibody (aPLa), these antibodies have been described in patients with SCA. AIMS This study was designed to determine the frequency of LA in SCA patients with CLU compared with those without CLU. MATERIALS AND METHODS Study design is a descriptive, cross-sectional one. Thirty-three SCA patients with CLU and 33 patients without CLU were screened for the presence of LA using the Kaolin clotting time (KCT), which is an important assay, and Kaolin clotting time index was calculated. Means were compared using the students' t test, proportions were compared using the chi-square test, level of significance was set at 0.05, odds ratio was calculated. RESULTS About 18.18% of patients with CLU had LA, compared with 6.06% among controls (P < 0.05); odds ratio was 3.44 (95% CI 0.64 - 18.51). CONCLUSIONS We conclude that SCA patients with CLU may be more likely to develop LA, and this may be related to the degree of hemolysis. Further studies are required to find out if CLU and LA are a result of hemolysis or if LA is responsible for the higher incidence of hemolysis and CLU found among these patients.
Collapse
Affiliation(s)
- Edeghonghon E Olayemi
- From the Department of Haematology, University of Ghana Medical School, Accra, Ghana, University of Benin, Benin City, Nigeria.
| | - Godwin N Bazuaye
- From the Department of Haematology, University of Ghana Medical School, Accra, Ghana, University of Benin, Benin City, Nigeria.
| |
Collapse
|
39
|
Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 2009; 33:1-16. [PMID: 19205968 DOI: 10.1080/03630260802625709] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Sickle cell disease is an inherited disorder of hemoglobin (Hb) synthesis, caused by a single nucleotide substitution (GTG>GAG) at the sixth codon of the beta-globin gene, leading to the production of a defective form of Hb, Hb S. When deoxygenated, Hb S polymerizes, damaging the sickle erythrocyte and it is this polymerization that is the primary indispensable event in the molecular pathogenesis of sickle cell disease. Hb S polymerization results in a series of cellular alterations in red cell morphology and function that shorten the red cell life span and leads to vascular occlusion. Sickle cell disease vaso-occlusion is now known to constitute a complex multifactorial process characterized by recurrent vaso-occlusion, ischemia-reperfusion injury, and oxidative stress with consequent vascular endothelial cell activation that induces a chronic inflammatory state in sickle cell disease individual and is propagated by elevated levels of circulating inflammatory cytokines. Activation of the endothelium results in the induction of endothelial adhesion molecule expression that mediates red and white cell adhesion to the vessel wall and the formation of heterocellular aggregates, followed by secondary red cell trapping, all of which contribute to reduced blood flow and eventually obstruction of the micro-circulation. Reduced nitric oxide bioavailability, caused principally by its consumption by cell-free Hb, liberated during intravascular hemolysis, contributes to this process by facilitating vasoconstriction and adhesion molecule activity.
Collapse
Affiliation(s)
- Nicola Conran
- Hematology and Hemotherapy Center, School of Medical Sciences, UNICAMP, São Paulo, Brazil.
| | | | | |
Collapse
|
40
|
Canalli AA, Franco-Penteado CF, Traina F, Saad STO, Costa FF, Conran N. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Eur J Haematol 2007; 79:330-7. [PMID: 17680813 DOI: 10.1111/j.1600-0609.2007.00926.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The significance of the leukocyte in sickle cell disease (SCD) pathophysiology is becoming increasingly recognised; we sought to examine whether the chemotactic properties of neutrophils of SCD individuals may be altered and, further, to better understand the signalling events that mediate altered SCD neutrophil function. Adhesion to immobilised fibronectin (FN) and chemotaxis of control and SCD neutrophils were assessed using in vitro static adhesion assays and 96-well chemotaxis chamber assays. Adhesion assays confirmed a significantly higher basal adhesion of SCD neutrophils to FN, compared with control neutrophils. Chemotaxis assays established, for the first time, that SCD neutrophils demonstrate greater spontaneous migration and, also, augmented migration in response to IL-8, when compared with control neutrophils. Co-incubation of SCD neutrophils with KT5720 (an inhibitor of PKA) abrogated increased basal SCD neutrophil adhesion, spontaneous chemotaxis and IL-8-stimulated chemotaxis. Stimulation of SCD neutrophils with IL-8 also significantly augmented SCD neutrophil adhesion to FN with a concomitant increase in cAMP levels and this increase in adhesion was abolished by KT5720. Interestingly, the adhesive properties of neutrophils from SCD individuals on hydroxyurea therapy were not significantly altered and results indicate that a reduction in intracellular cAMP may contribute to lower the adhesive properties of these cells. Data indicate that up-regulated cAMP signalling plays a significant role in the altered adhesive and migratory properties in SCD neutrophils. Such alterations may have important implications for the pathophysiology of the disease and the cAMP-PKA pathway may represent a therapeutic target for the abrogation of altered leukocyte function.
Collapse
Affiliation(s)
- Andreia A Canalli
- The Haematology and Haemotherapy Centre, State University of Campinas-UNICAMP, Campinas, SP, Brazil
| | | | | | | | | | | |
Collapse
|